Factors Which Affect Breast Cancer And Also Double The Risk Of Death
We are all aware of Breast cancer and how deadly it can be. It affects both men and women the same and is the most invasive type of cancer in women. It is second to lung cancer in regards to deaths by cancer in women. Although the survival rate has improved, due to better screening and treatment options it is still as bad as it can be. There are more than 3 million people who have survived breast cancer. The chances of death in women from breast cancer has dropped to 2.7 percent. The chances of reducing the risk are by creating more awareness about the symptoms and new ways to screen the disease.
There are various factors which can cause breast cancer. In women, the breast consists of fat, tiny glands which produce milk and connective tissues for breastfeeding the infant. The Breast cancer usually starts in the inner lining of the milk ducts and spread to other parts of the body. Some of the risk factors are Age, genetics, history of breast lumps or cancer, body weight, alcohol consumption, dense breast tissues, long exposure to estrogen and breastfeeding, radiation exposure, hormone treatment, and certain occupational hazard. All these factors play a certain role in developing breast cancer in women.
A team of researchers have found that the threat of demise from this cancer is almost twice for patients who have more heterogeneity of the estrogen receptor compared to sufferer with less heterogeneity. The study also highlighted that the risk of demise was higher in the span of 25 years. This was also true for Luminal A type of breast cancer. It is a subtype and has a good prognosis. The most common type of breast cancer is estrogen receptor positive also known as the hormone-sensitive breast cancer.
In this case, the tumor uses the female hormone estrogen to grow. Patients who develop this type of cancer always have the high risk of death due to this disease. Patients with estrogen receptor issues can also change the way of how the breast cancer tumor spreads. This also affects the survival chances of these patients. The team of scientists from both Sweden and America worked together to discover if the patients suffering from breast cancer with the high heterogeneity of the estrogen receptor have a high mortality rate compared to other breast cancer patients. The team studied the case of 593 such patients in a clinical study. The patients were treated with tamoxifen and no systemic therapy post surgery was done.
It was found that the mortality rate of the patients with the intra-tumor heterogeneity of the estrogen receptor was twice in the first 25 years after the diagnosis compared to other patients. This is true even for patients with Luminal A breast cancer subtype and high intra-tumor heterogeneity for the estrogen.